VahatiCor, Inc.

VahatiCor, Inc. is a US-based company that develops advanced medical devices, focusing on innovative solutions for treating coronary microvascular dysfunction through its proprietary technology. VahatiCor, Inc. specializes in creating medical devices targeted at coronary health issues.

Founded in 2021 and headquartered in Santa Clara, US, the company has undergone a significant strategic focus toward advanced interventional therapies. It was established with the vision to address critical health challenges and has secured a total funding of USD 21. 18 mn through a Series B round led by S3 Ventures, with participation from Intuitive Ventures, as of November 2025. The funding is a part of larger USD 32.

38 million round. VahatiCor, Inc. specializes in developing innovative medical devices, with its flagship product being the A-FLUX Reducer System®. This system addresses coronary microvascular dysfunction, alleviating chronic symptoms such as chest pain and shortness of breath.

Employing Swiftcell® Technology for rapid cardiac blood flow redistribution, the A-FLUX Reducer System® targets millions suffering from this condition. The company aims to expand its market presence, particularly in the United States, offering new therapeutic options in healthcare. VahatiCor's revenue generation model revolves around the commercialization of the A-FLUX Reducer System®, which is currently in investigational studies and clinical trials. The company typically engages in partnerships with hospitals and healthcare providers to integrate advanced treatment solutions for patients with coronary microvascular dysfunction.

The pricing structure will align with standard practices in the medical technology sector, typically negotiated on a per-unit basis, reflecting the advanced technology costs involved. VahatiCor, Inc. plans to utilize the recent funding of USD 21. 18 mn from its Series B round to advance the SERRA-I enrollment and develop necessary engineering capabilities for future studies and regulatory preparations.

The company aims to expand into major healthcare markets in the United States and is focused on launching additional treatment options by 2026, thus broadening its impact on patients suffering from coronary microvascular dysfunction.